Page last updated: 2024-12-07

triclabendazole sulfoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID127657
SCHEMBL ID10533601
MeSH IDM0225964

Synonyms (35)

Synonym
triclabendazole sulfoxide
6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfinyl-1h-benzimidazole
100648-13-3
tcbz-sx
ky3o5e011u ,
unii-ky3o5e011u
5-chloro-6-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-1h-benzimidazole
1h-benzimidazole, 5-chloro-6-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-
1h-benzimidazole, 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-
6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-1h-benzimidazole
AKOS015895881
SCHEMBL10533601
6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-1h-benzo[d]imidazole
triclabendazole metabolite m7
cga-110752
triclabendazole for veterinary use impurity a [ep impurity]
cgp023031
AKOS028112248
triclabendazole sulfoxide, vetranal(tm), analytical standard
triclabendazole-sulfoxide
FT-0760193
triclabendazole-sulfoxide 100 microg/ml in acetonitrile
BCP13966
Q27282496
DTXSID80905640
CS-0129507
triclabendazole sulfoxide;6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-1h-benzimidazole
6-chloro-5-(2,3-dichlorophenoxy)-2-methanesulfinyl-1h-1,3-benzodiazole
HY-136450
5-chloro-6-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-1h-benzimidazole (triclabendazole sulfoxide)
mfcd09038493
SY276987
5-chloro-6-(2,3-dichlorophenoxy)-2-(methylsulfinyl)-1h-benzo[d]imidazole
E84986
1ST5583

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"A comparative pharmacokinetic study was conducted to determine the order and the rate of absorption of triclabendazole (TCBZ) in cattle and sheep."( Pharmacokinetic disposition of triclabendazole in cattle and sheep; discrimination of the order and the rate of the absorption process of its active metabolite triclabendazole sulfoxide.
Errecalde, JO; Fernandez, C; Formentini, EA; Hernández, EM; Lucas, MF; Mestorino, N; Modamio, P, 2008
)
0.54

Compound-Compound Interactions

ExcerptReferenceRelevance
"The use of polypharmacy in the present day clinical therapy has made the identification of clinical drug-drug interaction risk an important aspect of drug development process."( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018
)
0.48
"In vitro drug-drug interaction potential of test compounds was investigated in two stages; 1) assessment of CYP450 inhibition potential of test compounds using human liver microsomes (HLM); and 2) assessment of test compounds as substrate of Phase I enzymes; including CYP450, FMO, AO and MAO using HLM, recombinant human CYP enzymes (rhCYP), Human Liver Cytosol (HLC) and Human Liver Mitochondrial (HLMit)."( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018
)
0.48
", perpetrator and/or victim drug) to overcome any imminent risk of potential clinical drug-drug interaction when sulfoxide/sulfone metabolite(s) generating drugs are coadministered in therapy."( In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone.
Giri, P; Giri, S; Gupta, L; Joshi, V; Naidu, S; Patel, N; Srinivas, NR, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
"A comparative pharmacokinetic study was conducted to determine the order and the rate of absorption of triclabendazole (TCBZ) in cattle and sheep."( Pharmacokinetic disposition of triclabendazole in cattle and sheep; discrimination of the order and the rate of the absorption process of its active metabolite triclabendazole sulfoxide.
Errecalde, JO; Fernandez, C; Formentini, EA; Hernández, EM; Lucas, MF; Mestorino, N; Modamio, P, 2008
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (6.67)18.2507
2000's10 (33.33)29.6817
2010's16 (53.33)24.3611
2020's2 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.89 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]